卡瑞利珠单抗联合阿帕替尼治疗十二指肠癌1例 - betway必威登陆网址

国际肿瘤学杂志››2022,Vol. 49››Issue (7): 447-448.doi:10.3760/cma.j.cn371439-20210709-00086

• 病例报道 •上一篇

卡瑞利珠单抗联合阿帕替尼治疗十二指肠癌1例

徐忠玲(), 王珏, 郑广, 何欣

齐齐哈尔医学院附属第三医院肿瘤一科,齐齐哈尔 161000

收稿日期:2021-07-09修回日期:2022-01-12出版日期:2022-07-08发布日期:2022-09-19
通讯作者:徐忠玲 E-mail:xuzhongling2009@126.com

Received:2021-07-09Revised:2022-01-12Online:2022-07-08Published:2022-09-19

摘要/Abstract

摘要：

十二指肠癌是一种罕见且侵袭性高的恶性肿瘤,目前尚无标准治疗方案。现报道1例十二指肠癌术后复发致恶性肠梗阻患者行卡瑞利珠单抗联合阿帕替尼治疗获得良好效果的病例,并对其治疗方案进行分析。

徐忠玲, 王珏, 郑广, 何欣. 卡瑞利珠单抗联合阿帕替尼治疗十二指肠癌1例[J]. 国际肿瘤学杂志, 2022, 49(7): 447-448.

图/表3

参考文献11

[1]	Platoff RM, Kellish AS, Hakim A, et al. Simple versus radical resection for duodenal adenocarcinoma: a propensity score matched analysis of national cancer database[J]. Am Surg, 2021, 87(2): 266-275. DOI: 10.1177/0003134820951432. doi:10.1177/0003134820951432
[2]	边志民. 恶性肠梗阻的治疗[J]. 中国医师杂志, 2020, 22(11): 1601-1605. DOI: 10.3760/cma.j.cn431274-20201026-01446. doi:10.3760/cma.j.cn431274-20201026-01446
[3]	Pedersen K, Foster N, Overman M, et al. O-007-ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA)[J]. Ann Oncol, 2019, 30(Suppl-4): iv128. DOI: 10.1093/annonc/mdz154.006. doi:10.1093/annonc/mdz154.006
[4]	Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical be-nefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018, 36(8): 773-779. DOI: 10.1200/JCO.2017.76.9901. doi:10.1200/JCO.2017.76.9901
[5]	Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2020, 38(1): 1-10. DOI: 10.1200/JCO.19.02105. doi:10.1200/JCO.19.02105pmid:31682550
[6]	Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Respir Med, 2021, 9(3): 305-314. DOI: 10.1016/S2213-2600(20)30365-9. doi:10.1016/S2213-2600(20)30365-9
[7]	Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011. DOI: 10.1158/1078-0432.CCR-20-2571. doi:10.1158/1078-0432.CCR-20-2571
[8]	Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial[J]. JAMA, 2021, 326(10): 916-925. DOI: 10.1001/jama.2021.12836. doi:10.1001/jama.2021.12836
[9]	程传耀, 解智慧, 柴慧芳, 等. mFOLFOX6方案联合卡瑞利珠单抗对微卫星不稳定直肠癌患者免疫功能的影响[J]. 肿瘤基础与临床, 2021, 34(5): 410-413. DOI: 10.3969/j.issn.1673-5412.2021.05.012. doi:10.3969/j.issn.1673-5412.2021.05.012
[10]	Chen J, Quan M, Chen Z, et al. Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial[J]. J Cancer Res Clin Oncol, 2020, 146(10): 2651-2657. DOI: 10.1007/s00432-020-03251-5. doi:10.1007/s00432-020-03251-5
[11]	Waterhouse DM, Garon EB, Chandler J, et al. Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153[J]. J Clin Oncol, 2020, 38(33): 3863-3873. DOI: 10.1200/JCO.20.00131. doi:10.1200/JCO.20.00131

相关文章3

编辑推荐

Metrics

本文评价